AOD-9604 (HGH Fragment 176-191) Safety in Adolescents Aged 12, 17

What Is AOD-9604 and Why Is the Adolescent Question Being Asked?

AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone, corresponding to positions 176, 191 of the GH polypeptide chain. It was originally developed by Metabolic Pharmaceuticals (Melbourne, Australia) as an oral anti-obesity agent under the identifier MTP-13. The compound stimulates lipolysis and inhibits lipogenesis in adipose tissue. Critically, it does not activate the full GH receptor, a distinction Heffernan et al. established in animal models published in Endocrinology in 2001 [1].

The question of adolescent use is surfacing because obesity prevalence in U.S. teenagers has reached 20.3% as of the most recent CDC National Health and Nutrition Examination Survey cycle [2]. Parents and some clinicians are searching for options beyond behavioral intervention. AOD-9604 circulates on social media as a "safer GH fragment" because it lacks the receptor-binding domain that causes acromegalic side effects in adults. That framing is misleading for a developing body, and the sections below explain exactly why.

Compounding pharmacies operating under USP 503A regulations may legally prepare AOD-9604 for individual patients in the United States. The FDA has not approved AOD-9604 as a finished drug product for any indication in any age group [3]. The absence of approval is not a technicality. It reflects the failure of Metabolic Pharmaceuticals' Phase III oral program and the total absence of pediatric pharmacokinetic or safety data.

The Complete Absence of Pediatric Trial Data

Zero published randomized controlled trials exist for AOD-9604 in patients younger than 18. That is not a gap that can be bridged by extrapolating adult data.

The adult evidence base itself is thin. Metabolic Pharmaceuticals completed six Phase I/II studies and one Phase III trial (AOD9604-007) in adults between 1998 and 2007. The Phase III trial did not demonstrate statistically significant weight loss versus placebo in obese adults after 24 weeks at any tested oral dose [4]. The program was discontinued. No pediatric safety, pharmacokinetic, or pharmacodynamic data were collected at any stage of that development program.

The FDA's Pediatric Research Equity Act (PREA) requires sponsors to conduct pediatric studies for new drugs that may be used in children [5]. Because AOD-9604 never received adult approval, PREA requirements were never triggered, meaning no sponsor has ever been compelled to study the compound in minors. The result is a complete evidence vacuum. Prescribing AOD-9604 to a 14-year-old is pharmacological experimentation without institutional review board oversight, parental informed-consent frameworks for investigational drugs, or post-market safety surveillance.

The American Academy of Pediatrics' 2023 clinical practice guideline on pediatric obesity, the first comprehensive AAP guideline in 15 years, lists intensive health behavior and lifestyle treatment, orlistat, and GLP-1 receptor agonist pharmacotherapy as evidence-based options for adolescents [6]. AOD-9604 does not appear. It is not an oversight.

Growth Plate and Skeletal Development Risks

Open physes are the central structural reason AOD-9604 is contraindicated in adolescents. Full stop.

Longitudinal bone growth occurs at epiphyseal growth plates (physes), which remain open and biologically active until late adolescence. In females, physeal closure typically completes between ages 14, 16; in males, between ages 16, 18, though both ranges vary considerably by individual [7]. Any agent that modulates growth hormone signaling pathways, even indirectly, carries the theoretical potential to alter chondrocyte proliferation and differentiation within these zones.

AOD-9604 does not bind the GH receptor in the canonical sense. However, Heffernan et al. demonstrated that the fragment retains biologic activity at adipose tissue, and its downstream effects on IGF-1 secretion in a developing hypothalamic-pituitary axis have never been characterized [1]. IGF-1 is the primary mediator of physis-level growth. The FDA-approved prescribing information for recombinant human GH products, somatropin formulations including Genotropin, Norditropin, and Humatrope, explicitly lists epiphyseal closure as both a therapeutic endpoint and a contraindication trigger, reflecting decades of pharmacovigilance data that no analogous program exists for AOD-9604 [8].

Peak bone mineral density accrual occurs predominantly between ages 11 and 18, with approximately 90% of adult peak bone mass deposited during this window [9]. Disrupting GH-axis signaling during this period carries consequences that may not manifest until the third or fourth decade of life as reduced bone density and elevated fracture risk. No safety monitoring framework exists to detect those consequences in AOD-9604 users.

Hypothalamic-Pituitary-Gonadal Axis Considerations

Adolescence is defined by the activation and maturation of the hypothalamic-pituitary-gonadal (HPG) axis. Gonadotropin-releasing hormone pulse frequency increases, triggering the LH/FSH surges that drive puberty. The GH axis and the HPG axis are not independent. Endogenous GH secretion rises sharply during mid-puberty, reaching peak amplitudes that are three to five times higher than adult values, as documented in studies of 24-hour GH secretory profiles in adolescents [10].

Introducing an exogenous peptide that modulates lipolysis through GH-fragment activity into this precisely timed hormonal environment carries risks that are genuinely unknown. "Unknown" here means no published pharmacokinetic model, no published receptor-occupancy study in adolescent tissue, and no published case series capturing adverse hormonal outcomes. The endocrine literature does not show that AOD-9604 is safe in this context. It shows only that the question has never been studied.

The Endocrine Society's clinical practice guideline on growth hormone deficiency in children specifies that GH-axis-modulating therapy requires documented biochemical deficiency, standardized stimulation testing, and regular IGF-1 monitoring during treatment [11]. That framework exists because the developing HPG-GH network is sensitive, consequential, and difficult to repair once disrupted. AOD-9604 bypasses every element of that framework when dispensed through a compounding pharmacy without a documented pediatric indication.

Mental Health and Disordered Eating Considerations in Ages 12, 17

Weight-focused pharmacotherapy in adolescents carries a mental health overlay that has no direct parallel in adult prescribing. Body image concerns, disordered eating behaviors, and eating disorders (anorexia nervosa, bulimia nervosa, avoidant/restrictive food intake disorder) peak in incidence between ages 12 and 20 [12]. The National Eating Disorders Association estimates that eating disorders affect approximately 9% of the U.S. population at some point in their lifetime, with adolescent females representing the highest-risk demographic.

Any pharmacological agent marketed as a "fat-loss peptide" carries the potential to reinforce pathological weight-focused behaviors in this population. The AAP's 2023 obesity guideline explicitly states: "Weight-loss interventions for children and adolescents should be delivered within a framework that minimizes weight stigma and screens for disordered eating prior to initiation of pharmacotherapy" [6]. AOD-9604 compounding prescriptions do not come with that framework attached.

Screening tools validated for adolescent use include the SCOFF questionnaire (sensitivity 84.6%, specificity 89.6% for detecting eating disorders in adolescent populations) [13] and the EDE-Q adapted for younger patients. No AOD-9604 prescribing protocol for adolescents exists that incorporates these screens, because no such prescribing protocol should exist.

FDA Regulatory Status and 503A Compounding Implications

AOD-9604 is not FDA-approved for any indication. In the United States, it may be compounded by 503A pharmacies for individual patients under a valid prescription from a licensed practitioner. The FDA's guidance on compounded drug products makes clear that compounding is not a regulatory shortcut to prescribing unapproved drugs to populations excluded from clinical trials [3].

In November 2023, the FDA finalized its position that peptides including certain growth hormone secretagogues present "difficult to compound" characteristics and may not be appropriate for routine compounding [14]. AOD-9604 remains in an unresolved regulatory category. The practical implication for clinicians: prescribing AOD-9604 to a minor under 503A exposes the prescriber to liability for an off-label, unapproved agent in a population with zero supporting trial data, in a regulatory environment that is actively narrowing the permissible scope of peptide compounding.

The FDA adverse event reporting system (FAERS) contains case reports for compounded peptide products, but the voluntary nature of FAERS reporting and the absence of a denominator (number of patients exposed) make signal detection unreliable for low-volume compounded agents [15]. For AOD-9604 in adolescents specifically, FAERS signal is essentially zero, not because the drug is safe, but because the prescribing volume in this age group is (appropriately) near zero and because clinicians who do prescribe it off-label are not reliably filing adverse event reports.

Evidence-Based Weight Management Alternatives for Adolescents

Adolescents aged 12, 17 with obesity have several evidence-based pharmacological options that carry actual pediatric safety data.

Orlistat 120 mg three times daily is FDA-approved for patients aged 12 and older. The key pediatric trial (N=357, ages 12, 16) showed 0.55 kg/m² BMI reduction versus 0.31 kg/m² placebo over 52 weeks, alongside improvements in insulin sensitivity [16]. The effect size is modest, and gastrointestinal tolerability is a limiting factor, but the safety profile in adolescents is characterized.

Liraglutide 3 mg daily (Saxenda) received FDA approval for chronic weight management in adolescents aged 12 and older in December 2020, based on the SCALE Teens trial. In SCALE Teens (N=251, ages 12, 17, BMI at or above the 95th percentile), liraglutide 3 mg produced a 5.0% reduction in BMI standard deviation score versus a 1.6% increase in the placebo group after 56 weeks (P<0.001) [17]. Nausea was the most common adverse event, consistent with the adult GLP-1 profile.

Semaglutide 2.4 mg weekly (Wegovy) was approved by the FDA for adolescents aged 12 and older in December 2022. The STEP TEENS trial (N=201, ages 12, 17) demonstrated a 16.1% mean body weight reduction with semaglutide versus a 0.6% reduction with placebo at 68 weeks [18]. That 15.5 percentage-point difference is the largest pharmacotherapy-driven weight reduction ever documented in a pediatric randomized controlled trial.

These three agents have documented pediatric pharmacokinetic profiles, randomized trial safety data, FDA-approved prescribing information for adolescents, and post-market surveillance networks. AOD-9604 has none of those features.

The HealthRX Prescribing Decision Framework for AOD-9604 in Minors

The HealthRX medical team has developed a three-question clinical screen applied before any peptide prescription is considered for a patient under 18. If any answer is "no," the prescription is declined and the patient is routed to evidence-based alternatives.

Question 1: Does a published, peer-reviewed randomized controlled trial exist demonstrating safety and efficacy of this peptide in the patient's age group?

For AOD-9604 in patients aged 12, 17: No.

Question 2: Has the FDA approved this compound for the proposed indication in this age group, or does a valid IND exist covering this population?

For AOD-9604 in patients aged 12, 17: No.

Question 3: Can the prescribing clinician document that all evidence-based pharmacological alternatives appropriate for this age group have been considered and either tried or declined for a documented reason?

This third question is a procedural gate, not a disqualifier. But for the first two questions, the answer for AOD-9604 in adolescents is unambiguous. The HealthRX medical team does not prescribe AOD-9604 to any patient younger than 18.

What Clinicians Should Document When Declining AOD-9604 for an Adolescent

A clear, dated clinical note protects the patient, the family, and the prescribing clinician. The documentation should include the following elements.

The reason for the request should be recorded (e.g., parental inquiry prompted by social media content, patient request following online research). The absence of pediatric trial data should be stated explicitly, with reference to the failed Phase III adult program. Growth plate status and current pubertal stage (Tanner staging) should be documented, since that information is directly relevant to the risk assessment [7]. The clinician should record which evidence-based alternatives were discussed and whether a referral to a pediatric endocrinologist or registered dietitian was offered.

Tanner staging takes approximately two minutes and provides an objective, documentable record of physical development. A patient at Tanner Stage II has substantially more open physis activity than one at Tanner Stage V; the risk profile, while uncharacterized for AOD-9604 at any Tanner stage, is most concerning in the earlier stages where growth velocity is highest [7].

Monitoring Requirements If a Patient Has Already Been Exposed

Some patients arrive at HealthRX having already received AOD-9604 from another provider or via direct online purchase. The clinical response is not dismissal. It is structured monitoring.

Baseline labs should be drawn at first contact: IGF-1, fasting glucose, HbA1c, a lipid panel, and a comprehensive metabolic panel. Bone age radiography (left hand and wrist X-ray) provides a baseline physeal status assessment that can be repeated if symptoms develop [8]. The Endocrine Society guideline on GH deficiency management recommends IGF-1 monitoring every three to six months during any GH-axis-modifying therapy [11]. That interval is reasonable for adolescents with prior AOD-9604 exposure.

Growth velocity should be plotted using CDC growth charts at each visit [2]. A deceleration in growth velocity below the expected age- and sex-specific trajectory warrants immediate pediatric endocrinology referral, regardless of whether a causal link to AOD-9604 can be established. The precautionary principle applies: the compound has no proven benefit in this population and no safety data. Any abnormal finding tips the risk-benefit calculation firmly toward discontinuation.